Compare Teladoc Health Inc (TDOC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs Viatris Inc — how do they compare? Teladoc Health Inc trades at $6.1 (market cap $1.11B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 17.1× Teladoc Health Inc's market cap, and Viatris Inc pays a 2.91% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| TDOC | VTRS | |
|---|---|---|
Market Cap | $1.11B | $18.95B |
Sector | Health | Health |
52-Week High | $9.72 | $17.86 |
52-Week Low | $4.47 | $9.49 |
Enterprise Value | $1.37B | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Analyst consensus is a hold with a $8.88 price target, while recent news highlights leadership changes and ongoing legal investigations.
The outlook is cautious; while valuation ratios like P/S of 0.45 and EV/EBITDA of 6.5 appear attractive, persistent losses and negative ROE of -12.99% pose risks. Upside depends on profitability improvements under new CFO Michael Grasher, but investor sentiment is tempered by weak earnings and competitive pressures.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
